News Search Results
Jun 04, 2026, 08:31 ET MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall
More news about: MetaVia Inc.
Jun 04, 2026, 08:30 ET Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day
track record in supporting complex ADC/XDC programs from process development to commercial supply.The event also featured perspectives from biotechnology partners. Dr. Junhua Qiao, CTO of GenSci shared insights on effective collaboration models between biotech companies and CDMO partners, drawing
More news about: BioDlink Biopharm Co., Ltd.
Jun 04, 2026, 08:01 ET ARTAN Bio Raises $200,000 in Decentralized Funding to Advance Longevity Science Through Mutation-Specific Codon Suppression
ARTAN Bio, a longevity biotechnology company based in St. Petersburg, Florida, today announced the completion of a $200,000 seed raise. The raise will fund preclinical advancement of
More news about: ARTAN BIO
Jun 04, 2026, 07:00 ET HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026
BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced the
More news about: HotSpot Therapeutics
Jun 04, 2026, 06:30 ET Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.For more information on Bio‑Techne, please visit
More news about: Bio-Techne Corporation
Jun 04, 2026, 05:00 ET Muna Therapeutics Announces Nature Medicine Publication Validating Microglial State Transitions as Key Drivers of Alzheimer's
COPENHAGEN, Denmark and BOSTON, June 4, 2026 /PRNewswire/ -- Muna Therapeutics, a clinical-stage biotechnology company pioneering a new era of drug discovery for neurodegenerative diseases, today announced the publication of a seminal study in Nature Medicine:
More news about: Muna Therapeutics
Jun 03, 2026, 23:36 ET MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
South Korea, June 3, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct a single pivotal Phase 3 study for CARTISTEM® in the U.S. This milestone
More news about: MEDIPOST
Jun 03, 2026, 16:15 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
conditions of the stock option agreement covering the grant.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Jun 03, 2026, 11:30 ET SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.
GLP-compliant sites, positioning SGS as one of the most comprehensive, wholly owned analytical laboratory networks serving the pharmaceutical and biotechnology sectors worldwide.CMIC, INC. is a group company of CMIC HOLDINGS Co., Ltd. Following the acquisition, CMIC HOLDINGS Co., Ltd. will continue
More news about: SGS
Jun 03, 2026, 10:00 ET HkeyBio New Platform Launch: AIH, PBC, and IgAN Model Matrix Empowers "One Drug, Multiple Screens" in Autoimmune New Drug R&D
autoimmune and inflammatory diseases, dedicated to providing in vivo efficacy evaluation and translational medicine research services to global biotechnology companies, pharmaceutical enterprises, and research institutions.The company possesses capabilities encompassing rodent models, non-human
More news about: HKeyBio
Jun 03, 2026, 09:58 ET Switch Bioworks Advances Novel Microbial Fertilizer Into First-In-Class Field Trials
Switch Bioworks, a biotechnology company focused on sustainable fertilizer, today announced the launch of field trials of its novel microbial fertilizer, with authorization from
More news about: Switch Bioworks
Jun 03, 2026, 09:30 ET KrystoLens from Brain Navi Receives TFDA Certification, Set to Enter Taiwan Market
Brain Navi Biotechnology Achieves Key Regulatory Milestone Following Recognition at the 22nd National Innovation AwardZHUBEI, June 3, 2026 /PRNewswire/ -- Brain Navi Biotechnology announced that its KrystoLens, the single-use
More news about: Brain Navi Biotechnology
Jun 03, 2026, 09:30 ET KrystoLens from Brain Navi Receives TFDA Certification, Set to Enter Taiwan Market
Brain Navi Biotechnology Achieves Key Regulatory Milestone Following Recognition at the 22nd National Innovation AwardZHUBEI, June 3, 2026 /PRNewswire/ -- Brain Navi Biotechnology announced that its KrystoLens, the single-use
More news about: Brain Navi Biotechnology
Jun 03, 2026, 09:00 ET AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Jun 03, 2026, 08:57 ET Transverse Medical Appoints Thomas E. Chilcott as Chief Financial Officer
enterprises, providing leadership in finance, corporate strategy, governance, and operational execution. His experience spans medical technology, biotechnology, diagnostics, pharmaceuticals, and healthcare services, giving him a broad perspective on the challenges and opportunities facing innovative healthcare
More news about: Transverse Medical Inc.
Jun 03, 2026, 08:48 ET Introducing Beauty Crush Skincare: A New Standard in Regenerative Biotech Skincare
depends on these integrated processes functioning to enhance the skin barrier.Where Biotechnology Meets Organic LuxuryAt the heart of Beauty Crush is a fusion of cutting-edge biotechnology and certified organic ingredients. For the past 20 years, Karen has been dedicated to not accepting
More news about: Beauty Crush Skincare
Jun 03, 2026, 08:47 ET CounterX Therapeutics to Present at the 88th Annual College on Problems of Drug Dependence (CPDD) Scientific Meeting
pipelineSEATTLE, June 3, 2026 /PRNewswire/ -- CounterX Therapeutics, a biotechnology company focused on developing novel antibody therapeutics to end the opioid overdose and addiction epidemic, today announced that company leadership
More news about: CounterX Therapeutics
Jun 03, 2026, 08:46 ET NIANCE Expands Beyond Products into a Global Beauty & Longevity Ecosystem
science-backed skincare, nutritional supplements, and integrated longevity systems. Developed and manufactured in Switzerland, NIANCE combines advanced biotechnology with a holistic approach to supporting healthy aging, skin vitality, resilience, and long-term wellbeing.For further enquiries, please contact
More news about: NIANCE
Jun 03, 2026, 08:45 ET NIANCE Expands Beyond Products into a Global Beauty & Longevity Ecosystem
science-backed skincare, nutritional supplements, and integrated longevity systems. Developed and manufactured in Switzerland, NIANCE combines advanced biotechnology with a holistic approach to supporting healthy aging, skin vitality, resilience, and long-term wellbeing.For further enquiries, please contact
More news about: NIANCE
Jun 03, 2026, 08:22 ET ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.) TO SPACE AND DEFENSE ADVISORY BOARD
defense and space systems. The Company is also positioned to pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly
More news about: Rocket One Inc.
Jun 03, 2026, 08:07 ET QuantiPath Expands Food Safety Expertise with Addition of Dr. Tyler Stephens
QuantiPath, a biotechnology company advancing rapid pathogen detection and food safety diagnostics, today announced the addition of
More news about: QuantiPath
Jun 03, 2026, 08:00 ET Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced
More news about: Decoy Therapeutics, Inc
Jun 03, 2026, 07:00 ET Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases
Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced a global research collaboration and licensing agreement with Eli Lilly
More news about: Ascidian Therapeutics
Jun 03, 2026, 06:00 ET ElpasBio Completes Patient Enrollment in Phase III Pivotal Clinical Trial of AlloJoin®
SHANGHAI, June 3, 2026 /PRNewswire/ -- ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, today announced it completed patient enrollment in May in its China Phase III pivotal clinical trial
More news about: ElpasBio Holdings
Jun 03, 2026, 03:11 ET Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Pharmaceuticals, Inc.